A new tumor-associated antigen, called Tennessee Antigen (TAG), has been isolated from 95% of 154 primary human gastrointestinal tumors. In 208 patients with colorectal carcinoma 81% showed elevated levels of TAG in their sera. Our Phase I studies have resulted in the production of monoclonal antibodies (MoAb) and the development of an enzyme-linked immunoassay (EIA) to measure TAG in serum. In the present proposal, we will continue to produce and characterize MoAB using Western Blotting, immunofluorescence technique and immunohistochemical staining. The specificity, sensitivity and reproducibility of EIA will be studied. A prototype of TAG-EIA kit will be developed. The clinical utility of the TAG-EIA will also be evaluated. The objectives of this project are two-fold: l) Utilization of MoAB to TAG as reagents in pathological examination of cancers, 2) Commercialization of the TAG-EIA for Diagnosis and Management of Solid Cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44CA036650-03
Application #
2089140
Study Section
(SSS)
Project Start
1988-04-01
Project End
1990-03-31
Budget Start
1989-04-01
Budget End
1990-03-31
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Jcl Clinical Research Corporation
Department
Type
DUNS #
City
Knoxville
State
TN
Country
United States
Zip Code
37914